Acquisition of Corixa Corp

GlaxoSmithKline PLC
30 April 2005



               GLAXOSMITHKLINE TO ACQUIRE CORIXA CORPORATION 
            - DEVELOPER OF NOVEL VACCINE ADJUVANTS AND ANTIGENS 



LONDON (UK) AND PHILADELPHIA PA (USA) (29 APRIL 2005) -- GlaxoSmithKline plc
(NYSE: GSK) today announced the execution of a definitive agreement pursuant to
which GSK will acquire Corixa Corporation (Nasdaq: CRXA), a developer of
innovative products that regulate immunity, based in Seattle, WA (USA).  The
acquisition is structured as a cash for stock transaction, with the shareholders
of Corixa entitled to receive $4.40 per common share, representing a total value
of approximately $300 million.  The transaction, which has been unanimously
approved by Corixa's Board of Directors, is subject to approval of its
shareholders, regulatory clearance and certain other conditions.  GSK owns
approximately 8% of the outstanding Corixa shares and additional holders of
approximately 11% of the shares have agreed to vote their shares in favor of the
transaction. The transaction is expected to close in the third quarter of this
year.

As a result of the acquisition, GSK will acquire all scientific and business
programs, activities, assets and all related rights of Corixa.  Importantly, GSK
will acquire Corixa's manufacturing facility in Hamilton, MT (USA) which
produces Monophosphoryl Lipid A(R) (MPL(R)), a novel adjuvant contained in many
of the vaccines in GSK's pipeline. Furthermore GSK will no longer incur
royalties and other costs under the existing agreements in place between GSK and
Corixa nor will GSK incur royalties on future sales of their vaccines containing
MPL(R).

GSK will also acquire all assets related to a candidate prophylactic
tuberculosis vaccine and to a portfolio of candidate immunotherapeutic cancer
vaccines, being developed by GSK Biologicals and which contain antigens
discovered by Corixa pursuant to a 1998 multi-field vaccine discovery
collaboration between the parties.  As a result of the acquisition, GSK will no
longer be required to pay royalties related to these antigens.  Corixa's
portfolio also includes other compounds such as TLR4 agonists and antagonists.

Jean Stephenne, President of GSK Biologicals, said: "This is an important
strategic deal for GSK's vaccines division.  MPL(R), in particular, is an
important component in many of our most promising vaccines under development,
including Cervarix(R), our candidate vaccine targeting infection with the Human
Papilloma Virus (HPV), a leading cause of cervical cancer.

"In addition, this also represents the next step in progressing GSK's promising
tuberculosis vaccine approach and its cancer immunotherapeutics, as Corixa and
GSK have together developed considerable expertise in these areas over the
years."



GlaxoSmithKline - one of the world's leading research-based pharmaceutical and
healthcare companies - is committed to improving the quality of human life by
enabling people to do more, feel better and live longer.  For company
information, visit GlaxoSmithKline on the World Wide Web at www.gsk.com.



S M Bicknell
Company Secretary
29th April 2005



EDITORS NOTES:
ABOUT MPL(R)

MPL(R), a vaccine adjuvant from Corixa, is a key component in many of the novel
and GSK Bio proprietary adjuvant systems used in the future vaccine pipeline of
GSK Biologicals. MPL(R) is a component in GSK Bio's new hepatitis B vaccine,
Fendrix(R), which in February this year received regulatory approval from
Europe's CHMP.  MPL(R) is also included in the adjuvant system used in GSK Bio's
candidate malaria vaccine.  Other GSK Bio vaccines under development with MPL(R)
include a candidate prophylactic vaccine against cervical cancer caused by HPV,
a candidate prophylactic vaccine against herpes simplex and a number of
prophylactic vaccines specifically designed for infections in seniors such as
varicella zoster and the flu virus.  In addition MPL(R) is a key component in
the adjuvant system GSK Bio is testing in a number of its investigational cancer
immunotherapeutic vaccine approaches for the treatment of breast, lung, melanoma
or prostate cancers.

GSK now has clinical experience with MPL(R)-containing vaccines in over 80,000
doses and 30,000 subjects. In various clinical studies, GSK vaccines containing
adjuvant formulations which include MPL(R) as a component were shown to improve
antibody responses (kinetics and titers) and, importantly, to improve
cell-mediated immune responses important for persistence of an effective immune
response.


GSK BIOLOGICALS


GSK Biologicals, one of the world's leading vaccine manufacturers, is located in
Rixensart, Belgium.  Belgium is the centre of all GSK's activities in the field
of vaccine research, development and production.  GSK Biologicals employs more
than 1000 research scientists who are devoted to discovering new vaccines and
developing more cost-effective and convenient combination products to prevent
infections that cause serious medical problems worldwide. GSK Biologicals
employs 3600 employees in Belgium (more than 4450 worldwide).


GSK/CORIXA PREVIOUS RELATIONSHIP


GSK's relationship with Corixa Corporation also included a collaboration with
GSK's pharmaceuticals division on Bexxar, a therapeutic regimen for cancer
indications.  In December 2004 GSK acquired full marketing and development
rights for Bexxar worldwide from Corixa.


Enquiries:


Vaccine enquiries:                      Anne Walsh              +(32) 2 656 9831
                                                                +(32) 475835 782
UK Media enquiries:                     Philip Thomson          [phone]
                                        David Mawdsley          [phone]
                                        Chris Hunter-Ward       [phone]

US Media enquiries:                     Nancy Pekarek           +[phone]
                                        Mary Anne Rhyne         +[phone]
                                        Patricia Seif           +[phone]

European Analyst/Investor enquiries:    Duncan Learmouth        [phone]
                                        Anita Kidgell           [phone]
                                        Jen Hill                [phone]

US Analyst/ Investor enquiries:         Frank Murdolo           +[phone]
                                        Tom Curry               +[phone]




                      This information is provided by RNS
            The company news service from the London Stock Exchange